Saturday 17 October 2026
Export IMUX’s income statement to Excel — free account
Immunic, Inc.
IMUX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 60.0% and free cash flow fell 26.8%, each against the same quarter a year earlier.
6.97
0.13
−1.83%
Follow IMUX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 1,540.00 | 900.00 | 60.40 | 62.00 | 41.90 | 69.60 | 11.10 | 9.45 | 9.70 | 5.06 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 4,536.00 | 2,600.00 | 3,900.00 | 468.00 | 233.90 | 282.14 | 145.00 | 31.70 | 21.10 | 13.90 | |||||
| People | |||||||||||||||
| People | Employees | 87 | 97 | 10 | 26 | 28 | 55 | 66 | 77 | 91 | 92 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (41) | (52) | (12) | (35) | (44) | (93) | (120) | (94) | (101) | (97) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (41) | (52) | (12) | (35) | (44) | (93) | (120) | (94) | (101) | (97) | |||||
| Depreciation | 2 | 1 | 0 | 0 | 0 | 0 | 33 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (524.00) | (524.00) | (136.28) | (45.20) | (28.10) | (39.30) | (37.80) | (21.10) | (10.00) | (6.20) | |||||
| Cash flow | (455.72) | (405.59) | (114.97) | (36.97) | (29.45) | (35.19) | (20.47) | (15.98) | (8.46) | (5.51) | |||||
| Capex | (7.06) | (6.81) | (0.38) | 3.19 | (0.09) | (0.03) | (0.04) | (0.08) | (0.03) | (0.01) | |||||
| Free cash flow | (462.78) | (412.40) | (115.35) | (33.78) | (29.54) | (35.22) | (20.51) | (16.06) | (8.49) | (5.52) | |||||
| Book value | 744.54 | 502.45 | 135.19 | 75.58 | 101.37 | 53.74 | 35.73 | 6.53 | 1.84 | (0.43) | |||||
| Shares, m | 0 | 0 | 0 | 1 | 2 | 2 | 3 | 4 | 10 | 16 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (36) | (40) | (10) | (29) | (46) | (83) | (65) | (71) | (85) | (86) | ||||
| Capex | (1) | (1) | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (36) | (41) | (10) | (26) | (46) | (83) | (65) | (71) | (85) | (86) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 56 | 48 | 11 | 25 | 125 | 94 | 113 | 28 | 17 | (8) | ||||
| Total debt | — | — | 37 | 1 | 1 | 1 | 2 | — | — | — | |||||
| Net debt | (60) | (57) | (13) | (29) | (127) | (87) | (116) | (47) | (36) | (15) | |||||
| Shareholders’ equity | 58 | 50 | 11 | 58 | 159 | 127 | 114 | 29 | 18 | (7) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (53.52) | (83.72) | (31.30) | (88.07) | (37.65) | (60.56) | (90.24) | (102.84) | (211.22) | (299.36) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | (79.83) | (97.68) | (142.33) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (58.21) | (96.01) | (94.98) | (214.17) | (40.54) | (65.02) | (100.01) | (131.28) | (424.44) | (1,653.15) | |||||
Negative figures in brackets.
Charts ten years each
Immunic, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MIST Milestone Pharmaceuticals Inc. | $98.9M | — (loss-making) | — (loss-making) | −62.73% (below 0%: shrinking) | n/m | −80.81% (below 0%: shrinking) | 94.28% | (4,584.97%) | Compare |
| CBUS Cibus, Inc. | $98.6M | — (loss-making) | — (loss-making) | +6.54% (above 0%: growing) | n/m | +31.62% (above 0%: growing) | 100.00% | (1,300.30%) | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $97.4M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NRXS Neuraxis, Inc. | $97.2M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| IMUX Immunic, Inc. | $96.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | |
| ATRA Atara Biotherapeutics, Inc. | $96.9M | — (loss-making) | — (loss-making) | −96.42% (below 0%: shrinking) | n/m | +52.10% (above 0%: growing) | 69.68% | (749.21%) | Compare |
| ANIX ANIXA BIOSCIENCES INC | $96.7M | — (loss-making) | — (loss-making) | 0.00% | n/m | −17.14% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ICCC ImmuCell Corporation | $95.9M | 126× | — (loss-making) | +11.50% (above 0%: growing) | +233.33% (above 0%: growing) | +54.86% (above 0%: growing) | 33.92% | 26.93% | Compare |
| RANI Rani Therapeutics Holdings, Inc. | $94.8M | — (loss-making) | — (loss-making) | 0.00% | n/m | −55.29% (below 0%: shrinking) | 100.00% | (516.86%) | Compare |
| Median of peers | $97.0M | — | — | 0.00% | — | +25.02% | 77.77% | (313.51%) |
Immunic, Inc. (IMUX) key facts
- Immunic, Inc. (IMUX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, IMUX traded at $6.97, a market capitalization of $96.9 million.
- Return on equity was −1,653.2% and debt-to-equity 0.00.